Nasdaq

Lyra Therapeutics, Inc. Announces Definitive Agreement for Registered Direct Offering and Private Placement of Common Stock and Warrants

Lyra Therapeutics, Inc. has announced a definitive agreement to sell 423,372 shares of common stock and associated private placement warrants through a registered direct offering priced at $11.81 per ...
Seeking Alpha

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

PRINCETON, NJ, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has entered ...
Yahoo Finance

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CRANFORD, N.J., Dec. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius ...
Seeking Alpha

Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement

LEXINGTON, Mass., July 2, 2025 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, ...
Nasdaq

60 Degrees Pharmaceuticals, Inc. Closes Registered Direct Offering and Concurrent Private Placement Raising Approximately $1.075 Million

60 Degrees Pharmaceuticals closed a direct stock offering, raising approximately $1.075 million for working capital and corporate purposes. 60 Degrees Pharmaceuticals, Inc. has completed a registered ...
Morningstar

Largo Announces Reliance on Financial Hardship Exemption in Connection With Registered Direct Offering and Private Placement

Largo Inc. (“Largo” or the “Company”) (TSX: LGO) (NASDAQ: LGO) is pleased to announce further details in connection with the binding term sheet entered into with the senior lenders (“Lenders”) to ...
Morningstar

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Proceeds strengthen cash position and support commercial launch of LYMPHIR™, a novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL) CRANFORD, N.J., Dec. 9, 2025 /PRNewswire/ -- Citius ...